Rabbit monoclonal antibody against human CD44 protein and its application

By developing specific anti-human CD44 protein rabbit monoclonal antibodies, the problem of insufficient performance of anti-human CD44 protein monoclonal antibodies in the prior art is solved, and high accuracy and high sensitivity detection effects are achieved in immunoassays.

CN117777295BActive Publication Date: 2024-11-26WUHAN AIBO TAIKE BIOTECH CO LTD
View PDF 6 Cites 0 Cited by

Patent Information

Application Number
CN202410047257.6
Authority / Receiving Office
CN · China
Patent Type
Patents(China)
Current Assignee / Owner
Filing Date
2024-01-11
Publication Date
2024-11-26
Estimated Expiration
2044-01-11

AI Technical Summary

Technical Problem

In the prior art, monoclonal antibodies that have good performance against human CD44 protein are lacking in the art, and it is difficult to be used for high accuracy and high sensitivity immunoassays.

Method used

A rabbit monoclonal antibody against human CD44 protein, including specific light chain variable regions and heavy chain variable regions amino acid sequences, was developed to specifically recognize CD44 proteins in immune assays, including immunoblotting, enzymatic immunization. Analytical method, enzyme-linked immunosorbent assay, enzyme-linked immunospot method, immunofluorescence method, immunohistochemistry method and flow cytometry method.

Benefits of technology

It achieves high accuracy and high reliability detection of CD44 protein, avoids false positive or false negative results, and is suitable for clinical diagnosis and scientific research testing.

✦ Generated by Eureka AI based on patent content.

Smart Images

  • Figure CN117777295B_ABST
    Figure CN117777295B_ABST
Patent Text Reader

Abstract

The present invention belongs to the technical field of antibody preparation, and in particular to rabbit monoclonal antibodies against human CD44 protein and their applications. The amino acid sequences of the light chain CDR1-3 of the rabbit monoclonal antibody against human CD44 protein are shown in SEQ ID NO.5-7, respectively; the amino acid sequences of the heavy chain CDR1-3 are shown in SEQ ID NO.8-10, respectively. The rabbit monoclonal antibodies with the above CDR sequences prepared by the present invention can specifically recognize the recombinant CD44 protein expressed by genetic engineering and the CD44 protein naturally expressed in cells or tissues, and the antibody has high specificity, good affinity, and strong anti-interference ability, which ensures high accuracy and reliability in immunodetection of human CD44 protein, and has broad application prospects in clinical diagnosis and scientific research detection.
Need to check novelty before this filing date? Find Prior Art

Description

Technical Field

[0001] The present invention relates to the technical field of antibody preparation, in particular to rabbit monoclonal antibodies against human CD44 protein and applications thereof. Background Art

[0002] CD44 is a member of the transmembrane glycoprotein family. It is also known as homing cell adhesion molecule (HCAM), phagocytic glycoprotein-1 (Pgp-1), Hermes antigen, lymphocyte homing receptor, ECM-III or HUTCH-1. It is the main receptor for hyaluronic acid and the main component of the extracellular matrix. It is widely expressed in a variety of endothelial cells, mesenchymal stem cells, hematopoietic stem cells and mesoderm-derived cells and tissues, and is highly expressed in memory B cells and memory T cells. Physiologically, the main functions of CD44 protein can be summarized as follows: (1) As a lymphocyte homing receptor, it mediates the binding of lymphocytes to tall columnar endothelial cells in postcapillary venules, allowing lymphocytes to pass through the vascular wall and return to the lymphoid tissue; (2) The extracellular domain of CD44 protein has two highly conserved BX7B motifs, which can bind to matrix molecules such as hyaluronic acid and laminin in the extracellular matrix to regulate cell adhesion or migration in the extracellular matrix; (3) It participates in the activation process of lymphocytes. Pathologically, CD44 protein is expressed in a variety of tumor cells, especially tumor stem cells. The expression level is directly related to the tumor's invasive ability and is a recognized tumor stem cell marker. Studies have shown that in the proliferating malignant tumor cells, the expression of CD44 specific transcripts increases, and it participates in the invasion, differentiation and migration of tumors. Therefore, CD44 can be used for the early diagnosis of various benign and malignant tumors, the judgment of metastatic potential and the treatment of other aspects.

[0003] Immunoassay is an experimental method that uses the characteristics of antigen-antibody specific binding to achieve quantitative or qualitative detection. It has become an important method for diagnosing a variety of clinical diseases and provides an effective means to determine the cause of the disease and the location of the lesion. At present, common immunoassay methods include immunoblotting, immunofluorescence, immunohistochemistry, flow cytometry, etc. The core lies in the specific binding between antibodies and antigens. The quality of antibody performance directly determines the accuracy and reliability of immunoassay results. In view of the diagnostic and labeling value of CD44, the development of a monoclonal antibody that specifically binds to CD44 protein with strong anti-interference ability and high detection sensitivity has very important practical significance and broad application prospects for the realization of immunoassay CD44 protein. Summary of the invention

[0004] In view of the problem that the prior art lacks monoclonal antibodies against human CD44 protein with good performance and is difficult to use for immunoassay, the present invention provides rabbit monoclonal antibodies against human CD44 protein and provides the use of the rabbit monoclonal antibodies in immunoassay of human CD44 protein.

[0005] To achieve the above object, the present invention is specifically implemented through the following technical solutions:

[0006] The first aspect of the present invention provides a rabbit monoclonal antibody against human CD44 protein, comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region and the heavy chain variable region both comprise three complementary determining regions, wherein the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 are shown as SEQ ID NO.5, SEQ ID NO.6 and SEQ ID NO.7, respectively; the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 are shown as SEQ ID NO.8, SEQ ID NO.9 and SEQ ID NO.10, respectively.

[0007] Furthermore, the amino acid sequence of the light chain variable region is shown in SEQ ID NO.3, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.4.

[0008] Furthermore, it also includes a light chain constant region and a heavy chain constant region, the light chain constant region and the light chain variable region constitute a light chain, and the heavy chain constant region and the heavy chain variable region constitute a heavy chain; the amino acid sequence of the light chain is shown in SEQ ID NO.1, and the amino acid sequence of the heavy chain is shown in SEQ ID NO.2.

[0009] Furthermore, the rabbit monoclonal antibody is a full-length antibody or an antibody fragment with immunological activity; the antibody fragment is selected from at least one of a Fab fragment, a F(ab)2 fragment, a Fv fragment, a (Fv)2 fragment, a scFv fragment and a sc(Fv)2 fragment.

[0010] The second aspect of the present invention provides a nucleic acid molecule, which is used to encode the rabbit monoclonal antibody against human CD44 protein as described above.

[0011] Furthermore, the nucleotide sequence of the light chain variable region of the rabbit monoclonal antibody is shown in SEQ ID NO.12, and the nucleotide sequence of the heavy chain variable region is shown in SEQ ID NO.14.

[0012] Furthermore, the nucleotide sequence of the light chain of the rabbit monoclonal antibody is shown in SEQ ID NO.11, and the nucleotide sequence of the heavy chain is shown in SEQ ID NO.13.

[0013] The third aspect of the present invention provides a recombinant vector, which comprises the nucleic acid molecule described above.

[0014] The fourth aspect of the present invention provides the use of the above-mentioned rabbit monoclonal antibody against human CD44 protein, the above-mentioned nucleic acid molecule, and the above-mentioned recombinant vector in the preparation of a reagent and / or a kit for immunodetection of human CD44 protein.

[0015] Furthermore, the immunodetection method includes immunoblotting, enzyme immunoassay, enzyme-linked immunosorbent assay, enzyme-linked immunospot assay, immunofluorescence assay, immunohistochemistry or flow cytometry.

[0016] Furthermore, the immunoassay sample includes serum, cells or tissues, wherein the cells include one or more of human cervical cancer cells, human epidermal cancer cells and human breast cancer cells, and the tissues include one or more of human tonsils, human colon, human ovaries, human extranodal NK / T cell lymphoma, human colon invasive adenocarcinoma, human endometrioid carcinoma, human hepatocellular carcinoma, human prostate adenocarcinoma, human high-grade urothelial carcinoma, human ovarian serous carcinoma, human hepatobiliary carcinoma, human malignant glioma, human breast, human cervix, human lung, human brain (neuron), human breast invasive ductal carcinoma, human cervical squamous cell carcinoma, human lung squamous cell carcinoma, human small cell lung cancer, human placenta, human endometrial stromal sarcoma and human lung adenocarcinoma.

[0017] The advantages and positive effects of the present invention are:

[0018] The rabbit monoclonal antibody prepared by the present invention and having the above CDR sequence can specifically recognize the recombinant CD44 protein expressed by genetic engineering and the CD44 protein naturally expressed in cells or tissues, and the antibody has high specificity, good affinity and strong anti-interference ability, which ensures high accuracy and high reliability in immunodetection of human CD44 protein, and has broad application prospects in clinical diagnosis and scientific research detection. BRIEF DESCRIPTION OF THE DRAWINGS

[0019] In order to more clearly illustrate the technical solutions in the embodiments of the present invention, the following briefly introduces the drawings required for use in the description of the embodiments. Obviously, the drawings described below are only some embodiments of the present invention. For ordinary technicians in this field, other drawings can be obtained based on these drawings without creative work.

[0020] Figure 1 This is a gel electrophoresis diagram of CD44 protein in the supernatant and precipitate after the cells were broken and expressed using a prokaryotic expression system in Example 1 of the present invention;

[0021] Figure 2 This is the gel electrophoresis diagram of the CD44 protein purified in Example 1 of the present invention;

[0022] Figure 3Map of mammalian vector pBR322 used to construct rabbit monoclonal antibody expression vector against human CD44 protein, from left to right, respectively, maps of pRB322 vectors pre-carrying light chain constant region and heavy chain constant region;

[0023] Figure 4 This is a diagram showing the immunoblotting results of the binding of the rabbit monoclonal antibody to HeLa cells in Example 3 of the present invention;

[0024] Figure 5 This is an immunofluorescence detection diagram of the binding of the rabbit monoclonal antibody of Example 4 of the present invention to HeLa and A-341 cells;

[0025] Figure 6 This is an immunohistochemical detection diagram of the binding of the rabbit monoclonal antibody of Example 5 of the present invention to human tonsil and human liver tissue;

[0026] Figure 7 This is a flow cytometric detection diagram of the binding of the rabbit monoclonal antibody of Example 6 of the present invention to HeLa and MCF-7 cells. DETAILED DESCRIPTION

[0027] In order to make the purpose, technical solution and advantages of the present invention more clearly understood, the present invention is further described in detail below in conjunction with embodiments. The embodiments described herein are only used to explain the present invention and are not used to limit the present invention.

[0028] Based on the information contained in the present invention, it is easy for those skilled in the art to make various changes to the precise description of the present invention without departing from the spirit and scope of the appended claims. It should be understood that the scope of the present invention is not limited to the defined processes, properties or components, because these embodiments and other descriptions are only for the purpose of illustrating specific aspects of the present invention. In fact, various changes that a person skilled in the art or related fields can obviously make to the embodiments of the present invention are covered within the scope of the appended claims.

[0029] In order to better understand the present invention but not to limit the scope of the present invention, all the numbers and other numerical values ​​used in the present invention to express the amount, percentage, etc. should be understood as modified by the word "about" in all cases. Therefore, unless otherwise specified, the numerical parameters listed in the specification and the appended claims are approximate values, which may be changed according to the different ideal properties to be obtained. Each numerical parameter should at least be regarded as obtained according to the reported significant figures and by conventional rounding methods.

[0030] In addition, it should be noted that, unless otherwise defined, in the context of the present invention, the scientific and technical terms used should have the meanings commonly understood by those of ordinary skill in the art.

[0031] The meaning of the terms "include", "comprising", "containing", "having" and the like is non-restrictive, i.e., other steps and other ingredients that do not affect the result may be added. The term "and / or" should be regarded as a specific disclosure of each of the two specified features or components with or without the other. For example, "A and / or B" will be regarded as including the following situations: (i) A, (ii) B, and (iii) A and B.

[0032] In the context of the present invention, the terms "rabbit monoclonal antibody", "monoclonal antibody", "antibody" and "rabbit monoclonal antibody" and other similar words have the same meaning and can be used interchangeably, all referring to antibodies that specifically bind to human CD44 protein. The modifier "rabbit" indicates that the complementarity determining region (CDR) of the antibody is derived from a rabbit immunoglobulin sequence.

[0033] An antibody is an immunoglobulin molecule that can specifically bind to a target antigen or epitope through at least one antigen recognition site located in the variable region of an immunoglobulin (Ig) molecule. In the present invention, the term "antibody" should be interpreted in the broadest sense and includes different antibody structures, including but not limited to so-called full-length antibodies, antibody fragments, and their genetic or chemical modifications, as long as they exhibit the desired antigen-binding activity. Among them, "antibody fragment" refers to one or more parts or fragments of a full-length antibody. In typical examples, antibody fragments include: Fab, Fab', F(ab)2, F(ab')2, Fv, (Fv)2, scFv, sc(Fv)2.

[0034] A typical antibody molecule (full-length antibody) consists of two identical light chains (L) and two identical heavy chains (H). Light chains can be divided into two types, namely κ chain and λ chain; heavy chains can be classified into five types, namely μ, δ, γ, α and ε chains, and antibodies are defined as IgM, IgD, IgG, IgA and IgE, respectively. The amino acid sequences near the N-terminus of the heavy and light chains vary greatly, while the amino acid sequences of other parts are relatively constant. The regions near the N-terminus of the light and heavy chains where the amino acid sequences vary greatly are called variable regions (V), and the regions near the C-terminus where the amino acid sequences are relatively stable are called constant regions (C). The heavy chain variable region (VH) and the light chain variable region (VL) are usually the most variable parts of the antibody and contain antigen recognition sites. The VH and VL regions can be further subdivided into hypervariable regions (HVR) and framework regions (FR). The hypervariable regions are also called complementarity determining regions (CDRs), which are ring-shaped structures. The heavy chain CDR and the light chain CDR are closely together and cooperate with each other through the FR region, forming a surface that can complement the three-dimensional structure of the target antigen or epitope, which determines the specificity of the antibody and is the site where the antibody recognizes and binds to the antigen. The FR region is the more conservative part of VH and VL. They are generally in a β-folded configuration and are connected by three CDRs that form a connecting loop. Each VH and VL is usually composed of three CDRs and four FRs, arranged from the amino terminus to the carboxyl terminus in the following order: FR1, CDR1, FR2, CDR2, FR3, CDR3, FR4.

[0035] CDRs can be identified according to the Kabat definition, the Chothia definition, the accumulation of both the Kabat definition and the Chothia definition, the AbM definition, the contact definition, the IMGT unique numbering definition and / or the conformational definition, or any CDR determination method known in the art. As used herein, CDRs are defined by the Kabat numbering system.

[0036] The light chain constant region (CL) and the heavy chain constant region (CH) are not directly involved in the binding of antibodies to antigens, but they exhibit different effector functions, such as participating in antibody-dependent cytotoxicity of antibodies. The length of CL of different types of Ig (κ or λ) is basically the same, but the length of CH of different classes of Ig is different, such as IgG, IgA and IgD include CH1, CH2 and CH3, while IgM and IgE include CH1, CH2, CH3 and CH4. The amino acid sequences of the heavy chain and light chain constant regions of antibodies are well known in the art.

[0037] A full-length antibody is the most complete antibody molecular structure and has a typical Y-shaped molecular structure. Therefore, in the context of the present invention, "full-length antibody", "complete antibody" and "Y-shaped antibody" have the same meaning and can be used interchangeably.

[0038] The term "antigen-binding fragment (Fab)" refers to the region of an antibody molecule that can bind to an antigen. It consists of a complete light chain (variable region and constant region) and a partial heavy chain (variable region and a constant region fragment). By proteolytic cleavage of the full-length antibody, fragments such as Fab, F(ab')2, and Fab' can be obtained. For example, under the action of papain, IgG can be degraded into two Fab fragments and an Fc fragment; under the action of pepsin, IgG can be degraded into a F(ab')2 fragment and a pFc' fragment. The F(ab')2 fragment is further reduced to form two Fab' fragments. Because Fab has an antigen-binding region and a partial constant region, it not only has the same antibody-antigen affinity and excellent tissue penetration as a single-chain antibody (scFv), but also has a more stable structure, and is widely used in clinical diagnosis and treatment.

[0039] The term "variable fragment (Fv)" is located at the N-terminus of the antibody Fab fragment, contains only the variable region, and is composed of the variable regions of a light chain and a heavy chain. It is a dimer of VH and VL non-covalently bound (VH-VL dimer). The three CDRs of each variable region interact with each other to form an antigen binding site on the surface of the VH-VL dimer, which has the ability to recognize and bind to antigens, although the affinity is lower than that of a complete antibody.

[0040] The term "single-chain variable fragment (scFv)" refers to the smallest antibody fragment formed by connecting the heavy chain variable region (VH) and the light chain variable region (VL) through a flexible linker (generally composed of 10-25 amino acids), which retains the binding specificity of the original antibody to the antigen. The linker in the present invention is not particularly limited as long as it does not hinder the expression of the antibody variable regions connected to its two ends. Compared with full-length antibodies, scFv has the characteristics of small molecular weight, so it has higher penetration and lower immune side effects.

[0041] The full-length sequence of the antibody or antibody fragment of the present invention can be from a single species, such as a rabbit, or can be a chimeric or humanized antibody to reduce the body's rejection reaction while maintaining the required specificity and affinity. The term "chimeric antibody" refers to a portion of an antibody derived from a specific source or species, while the rest is derived from a different source or species. The term "humanized antibody" is a chimeric antibody of a non-human antibody such as a rabbit antibody CDR region and a human FR region. In some cases, the variable region of a non-human antibody is combined with a constant region of a human antibody, such as a human-rabbit chimeric antibody; in other cases, the CDR region of a non-human antibody is combined with a FR region and a constant region derived from a human antibody sequence, that is, the CDR region of a non-human antibody is grafted onto a human antibody framework (FR) sequence, and this framework sequence is derived from a single or multiple other human antibody variable region framework sequences. In the present invention, the CDR region in a chimeric antibody or humanized antibody is derived from a rabbit CDR region.

[0042] The term "monoclonal antibody" refers to a homogeneous antibody population, i.e., the individual antibodies constituting the population are identical except for possible naturally occurring mutations and / or post-translational modifications (e.g., isomerization, amidation) that may be present in small amounts. Monoclonal antibodies are highly specific, directed against a single antigen or epitope. "Monoclonal" indicates that the antibody is characterized by being obtained from a substantially homogeneous antibody population and should not be construed as limiting the structure, source, or preparation of the antibody. In certain embodiments, monoclonal antibodies are prepared by hybridoma methods, phage display methods, yeast display methods, recombinant DNA methods, single cell screening, or single cell sequencing methods.

[0043] The term "specific binding" is a well-known term in the art, and a molecule exhibits "specific binding" if it reacts with a specific target antigen or epitope more frequently, more rapidly, longer lastingly, and / or with greater affinity than with other target antigens or epitopes. "Specific binding" or "preferential binding" does not necessarily require (although it can include) exclusive binding.

[0044] In order to make the above-mentioned objects, features and advantages of the present invention more obvious and easy to understand, specific embodiments of the present invention are described in detail below with reference to the accompanying drawings.

[0045] An embodiment of the present invention provides a rabbit monoclonal antibody against human CD44 protein, comprising a light chain variable region and a heavy chain variable region, wherein the light chain variable region (VL) and the heavy chain variable region (VH) both comprise three complementary determining regions (CDRs), which are represented by CDR1, CDR2 and CDR3, respectively, wherein the amino acid sequences of the light chain CDR1, the light chain CDR2 and the light chain CDR3 are shown in SEQ ID NO.5, SEQ ID NO.6 and SEQ ID NO.7, respectively; the amino acid sequences of the heavy chain CDR1, the heavy chain CDR2 and the heavy chain CDR3 are shown in SEQ ID NO.8, SEQ ID NO.9 and SEQ ID NO.10, respectively.

[0046] The present invention uses the 20th to 178th amino acid fragment of the N-terminus of the human CD44 protein expressed by a prokaryotic expression system as an antigen, immunizes New Zealand white rabbits, and then obtains a rabbit monoclonal antibody against the human CD44 protein based on the monoclonal antibody development technology of single B lymphocyte screening and culture, and the antibody has good performance. Specifically, when human cervical cancer cells HeLa that highly express CD44 protein were detected by immunoblotting, only a single band was detected in the cell lysate, and the band size was consistent with expectations; when human cervical cancer cells HeLa and human epidermal cancer cells A-431 that highly express CD44 protein were detected by immunofluorescence, the antibody bound to the CD44 antigen and was accurately positioned, and the fluorescence signal was clear and bright; when positive and negative tissue samples that expressed and did not express CD44 protein were detected by immunohistochemistry, all positive and negative tissue samples could be accurately distinguished, the coloring in positive tissue samples was accurate, and there was no nonspecific staining in negative and positive tissue samples, with high detection sensitivity and specificity; further, when CD44 protein expressed on the cell surface was detected by flow cytometry, there was an obvious fluorescence transition on Hela cells and human breast cancer cells MCF-7, and the signal intensity was single. The above results prove that the rabbit monoclonal antibody prepared by the present invention and having the above CDR sequence can specifically recognize the recombinant CD44 protein expressed by genetic engineering and the CD44 protein naturally expressed in cells or tissues, and the antibody has high specificity, good affinity and strong anti-interference ability, which ensures high accuracy and high reliability in immunoassay, especially immunoblotting, immunofluorescence, immunohistochemistry and flow cytometry for detecting human CD44 protein, and is conducive to avoiding false positive or false negative results. Therefore, it is suitable for immunoassay of human CD44 protein and has broad application prospects in clinical diagnosis and scientific research detection.

[0047] Optionally, the light chain variable region (VL) and the heavy chain variable region (VH) both include a framework region (FR), wherein the four FRs and three CDRs of each chain are arranged alternately in sequence to form a variable region. The amino acid sequence of VL of the rabbit monoclonal antibody of the present invention is shown in SEQ ID NO.3, and the amino acid sequence of VH is shown in SEQ ID NO.4.

[0048] Optionally, the rabbit monoclonal antibody of the present invention further comprises a light chain constant region and a heavy chain constant region, CL and VL constitute a complete light chain, and CH and VH constitute a complete heavy chain. The constant region of an antibody can usually be obtained by public query, such as: searching for rabbit IgG gamma C reign to obtain CH through the IMGT online database (www.imgt.org), and searching for rabbit IgG Kappa Creign to obtain CL.

[0049] Specifically, the amino acid sequence of the light chain comprising CL is shown in SEQ ID NO.1, and the amino acid sequence of the heavy chain comprising CH is shown in SEQ ID NO.2. Correspondingly, CL is of κ type and CH is of IgG1 type.

[0050] The rabbit monoclonal antibody of the present invention can be a full-length antibody or an antibody fragment. The antibody fragment refers to a polypeptide that substantially retains the same biological function or activity as the full-length form of the rabbit monoclonal antibody. Specifically, the antibody fragment includes the CDR region (SEQ ID NO.5-10) as described above, and more preferably has the variable region (SEQ ID NO.3-4) as described above, thereby retaining a complete antigen recognition and binding site, and can bind to the same antigen CD44 protein as the full-length antibody, especially to the same epitope. The antibody fragments include but are not limited to: (i) Fab fragments, which are monovalent fragments consisting of the variable region and the first constant region of each heavy chain and light chain; (ii) F(ab)2 fragments, which are bivalent fragments comprising two Fab fragments connected by a disulfide bridge in the hinge region; (iii) Fv fragments, which are composed of one heavy chain variable region and one light chain variable region of an antibody; (iv) (Fv)2 fragments, which are composed of two covalently linked Fv fragments; (v) scFv fragments, which are Fv fragments consisting of a single polypeptide chain, in which one heavy chain variable region and one light chain variable region are connected by a linker; (vi) sc(Fv)2 fragments, which are formed by connecting two heavy chain variable regions and two light chain variable regions by a linker, etc. These antibody fragments can be obtained by conventional techniques known to those skilled in the art.

[0051] Another embodiment of the present invention provides a nucleic acid molecule, which is used to encode the rabbit monoclonal antibody against human CD44 protein as described above.

[0052] The nucleic acid molecule can be in the form of DNA (e.g., cDNA, genomic DNA, or synthetic DNA) or RNA (e.g., mRNA or synthetic RNA). DNA can be single-stranded or double-stranded, and can be a coding strand or a non-coding strand. The sequence of the nucleic acid molecule can be derived based on the amino acid sequence of the antibody by conventional means such as codon coding rules.

[0053] Illustratively, the nucleotide sequence of the light chain variable region of the rabbit monoclonal antibody of the present invention is shown in SEQ ID NO. 12, and the nucleotide sequence of the heavy chain variable region is shown in SEQ ID NO. 14. Further, the nucleotide sequence of the light chain is shown in SEQ ID NO. 11, and the nucleotide sequence of the heavy chain is shown in SEQ ID NO. 13. Those skilled in the art will appreciate that, due to the degeneracy of the genetic code, nucleic acid molecules other than the aforementioned examples can also encode the rabbit monoclonal antibody of the present invention, and therefore, the aforementioned examples of nucleic acid molecules should not be used as a limitation on the scope of protection of the present invention.

[0054] Another embodiment of the present invention provides a recombinant vector, which carries the nucleic acid molecule described above.

[0055] The starting vector for constructing the recombinant vector is any conventional vector in the art, as long as it can hold the nucleic acid molecule. Typical vectors include plasmids, viral vectors, bacteriophages, cosmids, and minichromosomes. Plasmids are the most common vector forms, and therefore, in the context of the present invention, vectors and plasmids are used interchangeably. Vectors can be cloning vectors or expression vectors, and cloning vectors can include selection markers and replication origins that match the cell type specified by the cloning vector, while expression vectors include regulatory elements (such as promoters, enhancers) expressed in specified host cells.

[0056] Nucleic acid molecules encoding heavy chains and light chains of antibodies such as the present invention can be cloned into a vector, and each nucleic acid sequence is connected to a suitable promoter downstream; for example, each nucleic acid sequence encoding heavy chains and light chains can be operably connected to different promoters, or, nucleic acid sequences encoding heavy chains and light chains can be operably connected to a single promoter, so that both heavy chains and light chains can be expressed by the same promoter. In other embodiments, nucleic acid molecules encoding heavy chains and light chains of antibodies such as the present invention can also be constructed into two vectors, which can be introduced into the same or different host cells. When the heavy chain and the light chain are expressed in different host cells, each chain can be separated from the host cell expressing it, and the separated heavy chain and light chain are mixed and incubated under suitable conditions to form antibodies. The selection of the aforementioned vectors and the regulatory elements contained in the vectors depends on the type of host cells used to produce antibodies.

[0057] Transformation of host cells with recombinant vectors can be carried out using conventional techniques well known to those skilled in the art. When the host is a prokaryotic organism such as Escherichia coli, competent cells that can absorb DNA can be harvested after the exponential growth phase and treated with the CaCl2 method or the MgCl2 method, or by microinjection, electroporation or liposome packaging. When the host is a eukaryotic organism, the following DNA transfection methods can be used: calcium phosphate coprecipitation method, as well as microinjection, electroporation, liposome packaging, etc.

[0058] The host cell can be a prokaryotic cell, such as a bacterial cell; or a lower eukaryotic cell, such as a yeast cell; or a higher eukaryotic cell, such as a mammalian cell. Representative examples include bacterial cells of Escherichia coli, Streptomyces, and Salmonella typhimurium, fungal cells such as yeast, insect cells of Drosophila S2 or Sf9, CHO, COS7, 293 series cells, etc. After obtaining a host cell transformed with the expression vector described above, the cell can be cultured under suitable conditions to express a monoclonal antibody, which can then be separated to obtain a purified antibody.

[0059] In a preferred embodiment, the above-mentioned recombinant vector is a mammalian expression vector pBR322, and the host cell is a human kidney epithelial cell (293F cell).

[0060] The embodiments of the present invention also provide the use of the above-mentioned rabbit monoclonal antibody against human CD44 protein, the above-mentioned nucleic acid molecule, and the above-mentioned recombinant vector in the preparation of a reagent and / or a kit for immunodetection of human CD44 protein.

[0061] The advantages of using the rabbit monoclonal antibody, nucleic acid molecule, and recombinant vector against human CD44 protein in preparing reagents and / or kits for immunodetection of human CD44 protein are the same as the advantages of the rabbit monoclonal antibody against human CD44 protein described above over the prior art, and will not be repeated here.

[0062] The rabbit monoclonal antibody against human CD44 protein of the present invention can be used for conventional immunoassays, including but not limited to: Western blot (WB), enzyme immunoassay (EIA), enzyme linked immunosorbent assay (ELISA), enzyme-linked immunospot (ELISPOT), immunofluorescence (IF), immunohistochemistry (IHC), flow cytometry (FCM), and can be used to detect recombinantly expressed human CD44 protein or natural CD44 protein from humans. The test samples include serum, cells or tissues, among which cells include but are not limited to: human cervical cancer cells HeLa, human epidermal cancer cells A-431 and human breast cancer cells MCF-7, and tissues include but are not limited to: human tonsils, human colon, human ovaries, human extranodal NK / T cell lymphoma, human colon invasive adenocarcinoma, human endometrioid carcinoma, human hepatocellular carcinoma, human prostate adenocarcinoma, human high-grade urothelial carcinoma, human ovarian serous carcinoma, human hepatobiliary carcinoma, human malignant glioma, human breast, human cervix, human lung, human brain (neuron), human breast invasive ductal carcinoma, human cervical squamous cell carcinoma, human lung squamous cell carcinoma, human small cell lung cancer, human placenta, human endometrial stromal sarcoma and human lung adenocarcinoma.

[0063] During immunoassay, the sample to be tested is contacted with the anti-CD44 antibody of the present invention, and the bound CD44 antibody is detected. In some embodiments, the anti-CD44 antibody can be directly coupled with a detectable label, and then the CD44 protein is qualitatively or quantitatively detected by observing the detectable label to produce a recognizable signal change. In other embodiments, the anti-CD44 antibody (primary antibody or capture antibody) is not labeled, but a secondary antibody (detection antibody) or other molecule that can bind to the anti-CD44 antibody is detectably labeled and coupled. For example, if the anti-CD44 antibody is rabbit IgG, the secondary antibody can be an anti-rabbit IgG antibody, thereby specifically binding to the anti-CD44 antibody through the secondary antibody coupled with a detectable label to produce a recognizable signal change.

[0064] Detectable labels for detection purposes include, but are not limited to, biotin, fluorescein, chemiluminescent groups, chemifluorescent groups, fluorescent proteins, enzymes (such as horseradish peroxidase, acid phosphatase), colloidal gold, colored magnetic beads, latex particles, radionuclides, detection antibodies, or combinations thereof.

[0065] The present invention is further described below in conjunction with specific examples. The experimental methods in the following examples where specific conditions are not specified are usually performed under conventional conditions, such as the conditions described in the Molecular Cloning Laboratory Guide (Fourth Edition) published by Cold Spring Harbor Laboratory, or usually under the conditions recommended by the manufacturer.

[0066] Example 1 Preparation of recombinant human CD44 protein antigen

[0067] In this example, E. coli Rosetta was used to express a gene sequence encoding a fragment of amino acids 20 (inclusive) to 178 (inclusive) of human CD44 protein, and a recombinant human CD44 protein with high purity was purified as an immunogen, and the recombinant human CD44 protein carried a GST tag and a His tag. The full-length gene sequence of human CD44 protein is shown in NM_000610.4, and the amino acid sequence of human CD44 protein at positions 20-178 is shown below:

[0068] AQIDLNITCRFAGVFHVEKNGRYSISRTEAADLCKAFNSTLPTMAQMEKALSIGFETCRYGFIEGHVVIPRIHPNSICAANNTGVYILTSNTSQYDTYCFNASAPPEEDCTSVTDLPNAFDGPITITIVNRDGTRYVQKGEYRTNPEDIYPSNPTDDDV (see SEQ ID NO. 15).

[0069] The preparation of recombinant human CD44 protein specifically includes the following steps:

[0070] 1) Construction of protein expression plasmid: A plasmid containing the human CD44 CDS sequence (from Wuhan Abotek Biotechnology Co., Ltd.) was used as a template, and a pair of specific primers (nucleotide sequence see SEQ ID NO.16-17) were used to amplify the target fragment from position 20 to position 178 of the N-terminus of the human CD44 protein. The PCR reaction system was as follows: 1 μL template, 1 μL template, 1 μL forward primer (10 mM), 1 μL reverse primer (10 mM), 25 μL Gloria Nova HS 2X Master Mix (from Wuhan Abotek Biotechnology Co., Ltd., product number RK20717) and 22 μL pure water (NF H2O); PCR amplification program: 98°C pre-denaturation for 30 s, followed by 30 cycles of 98°C for 10 s, 64°C for 30 s, and 72°C for 30 s, and finally kept at 72°C for 5 min, and the resulting reaction solution was stored at 4°C. The nucleic acid sequence (5'-3') of the primer pair for amplifying the sequence of amino acids 20-178 of the human CD44 protein (hereinafter referred to as CD44 (20-178aa)) is as follows:

[0071] CD44-F: ggttccgcgtggatccccggaagcgcagatcgatttgaatataac (see SEQ ID NO. 16);

[0072] CD44-R: tggtgatgatgatgcggccgctccacgtcatcatcagtagggttgc (see SEQ ID NO. 17).

[0073] After the amplified PCR product was purified, it was loaded into the prokaryotic expression vector pGEX-4T-AB1 by homologous recombination. The insertion sites were EcoRI and XhoI restriction sites. The plasmid was preserved after sequencing verification. The sequencing work was completed by Jinkairui Biotechnology Co., Ltd.

[0074] 2) Protein expression: The pGEX-4T-AB1 plasmid containing the CD44 protein 20-178AA sequence was transformed into the Escherichia coli Rosetta strain and incubated overnight at 37°C on LB agar plates (containing 50 μg / mL kanamycin and 50 μg / mL chloramphenicol) to obtain single colony transformants.

[0075] The single colony transformant was inoculated into a 10 mL polypropylene tube containing 2 mL LB culture medium (containing 50 μg / mL kanamycin and 50 μg / mL chloramphenicol) and cultured at 37°C and 220 rpm for 16 h until the OD 600nm The OD value was about 0.4-0.6. Then, 2 mL of culture of each strain was transferred to a 1 L flask containing 400 mL of LB expression medium and cultured at 37 °C and 220 rpm for another 3-4 h. 600nm When it reaches about 0.45-0.55, add 0.8mM IPTG and induce at 37℃ for 3-4h. Transfer the induced bacterial solution to a dry 500mL centrifuge bottle, balance it with an electronic scale, add pure water if the masses are not equal, centrifuge at 4000rpm for 10min, discard the supernatant, and collect the bacteria and store them in a -20℃ freezer.

[0076] First bacterial disruption: Take 30mL of lysis solution (50mM Tris+300mM NaCl) to suspend the bacteria, transfer the suspended bacterial solution to a 50mL round-bottom centrifuge tube, put it in an ice box, and fix it with ice; select the amplitude variable rod, put it in the lysis chamber, power 350W, lysis for 3s, interval 3s, countdown 5min, then place it in an ice-water mixture to cool for 5min, and repeat the above steps to lysis for 5min; after lysis, centrifuge at 9000rpm for 10min to obtain supernatant① and precipitate.

[0077] Second bacterial disruption: 30 mL of bacterial disruption solution (2 M urea + PBS buffer) was measured and poured into the precipitate, the precipitate was blown evenly, and transferred to a 50 mL round-bottom centrifuge tube, the power was 350 W, the bacteria were disrupted for 3 s, the interval was 3 s, and the disruption was performed for 0-5 min (the disruption time was determined by the amount and texture of the precipitate, and the bacterial solution was placed in ice cubes), and centrifuged at 9000 rpm for 10 min to obtain supernatant ② and inclusion bodies. The obtained supernatant ① and supernatant ② were diluted 2 times with Loading Buffer, and the inclusion bodies were diluted 2 times and 10 times; the obtained 2-fold diluted supernatant ① (referred to as "upper 1"), 2-fold diluted supernatant ② (referred to as "upper 2"), 2-fold diluted inclusion bodies (referred to as "*2"), and 10-fold diluted inclusion bodies (referred to as "*10") samples were subjected to SDS-PAGE gel electrophoresis, and the results were as follows: Figure 1 shown.

[0078] Depend on Figure 1 The results in Figure 2 show that CD44(20-178aa)-GST-His protein is mainly expressed in inclusion bodies. Therefore, inclusion bodies were collected for protein purification.

[0079] 3) Protein purification: CD44 protein was extracted and purified from inclusion bodies by affinity chromatography using His tag affinity chromatography resin (purchased from Huiyan Biotechnology, catalog number HQ060311001L). The SDS-PAGE gel electrophoresis of the purified CD44 protein is shown in the figure below: Figure 2 As shown, from left to right, lane 1 and lane 2 are 0.4 mg / mL and 0.2 mg / mL bovine serum albumin (BSA), respectively, lane 3 is inclusion body, lane 4 is flow-through in the purification process (abbreviated as "FT"), lane 5 is 2-fold dilution of collected CD44 protein (abbreviated as "*2"), lane 6 is Marker (abbreviated as "MK"), and lane 7 is CD44 protein solution that has been successfully renatured. The arrows in the figure indicate the positions of CD44 protein bands.

[0080] After separation and purification, a recombinant human CD44 protein with a purity greater than 80% was obtained, which contained a CD44 protein fragment, a glutathione sulfhydryltransferase (GST) tag and a histidine protein tag. The concentration of the recombinant human CD44 protein was 1.5 mg / mL.

[0081] Example 2 Preparation of rabbit monoclonal antibody against human CD44 protein

[0082] 1) Animal immunization: Two New Zealand white rabbits were immunized with the recombinant human CD44 protein purified in Example 1; 200 μg was administered to each white rabbit. Before the first immunization, the antigen was mixed with an equal amount of complete Freund's adjuvant (purchased from Sigma) to prepare an emulsion, which was injected subcutaneously at multiple points on the rabbit's abdomen and back. After the first immunization, 100 μg of the immunogen was mixed with an equal amount of incomplete Freund's adjuvant (purchased from Sigma) to prepare an emulsion every 3 weeks, which was injected subcutaneously at multiple points on the rabbit's abdomen and back for two booster immunizations. After three immunizations, rabbit serum samples were collected, and the serum was diluted at 1:243000 and the titer against human CD44 was determined by ELISA. The OD 450nm For rabbits with a blood pressure exceeding 0.2, 200 μg of the immunogen was injected subcutaneously at multiple points for booster immunization, and the spleen was removed three days later.

[0083] 2) Isolate B lymphocytes from the spleen: Take out a culture dish in a safety cabinet aseptically, add 30-40mL of basal culture medium, put a cell sieve, take out the spleen and put it in the cell sieve, cut off the excess connective tissue and fat on the rabbit spleen tissue, cut the spleen tissue into pieces and put it into the cell sieve for grinding, take a clean grinding rod, and use the end of the pressing part to crush and grind the tissue. The cells in the membrane will slowly come out, and after passing through the cell sieve, they will be suspended in the culture dish solution; wash the cell sieve with 10mL of basal culture medium, and collect the basal culture medium outside the cell sieve. Centrifuge at 400g for 5min at room temperature, remove the supernatant, retain the cells, add 13mL of RBC lysis solution at room temperature (purchased from Tiangen Biochemical Technology Co., Ltd., product number RT122-02), gently blow away the cell clusters with a pipette, and then time for 1min to lyse the red blood cells, add 37mL of basal culture medium, mix well, and terminate the red blood cell lysis, centrifuge at 400g for 5min at room temperature, remove the supernatant, retain the cells, add 40mL of basal culture medium placed at room temperature, and gently blow away the cell clusters with a pipette to resuspend the cells to complete the first wash, centrifuge at 400g for 5min at room temperature, remove the supernatant, retain the cells, add 20mL of basal culture medium placed at room temperature, and gently blow away the cell clusters with a pipette to resuspend the cells; filter the resuspended cells again through a cell sieve to remove the clumping cells, and then count the cells.

[0084] 3) B lymphocyte sorting and culture: see the patent "Method for efficiently isolating single antigen-specific B lymphocytes from spleen cells (Publication No.: CN110016462A)" and the patent "A B lymphocyte in vitro culture system and application (Publication No.: CN111518765A)".

[0085] 4) Cloning of the gene encoding rabbit monoclonal antibody: The supernatant of cultured B lymphocytes was used to identify positive clones that could bind to human CD44 protein using antigen-coated ELISA. The cells of the positive clones were collected, lysed, and then analyzed by Quick-RNA TM RNA was extracted according to the instructions of the MicroPrep kit (purchased from ZYMO, catalog number R1051) and reverse transcribed into cDNA. Using the aforementioned cDNA as a template, the light chain variable region (VL) and heavy chain variable region (VH) coding genes of the naturally paired rabbit monoclonal antibody were amplified from the cDNA of the positive clone by PCR; wherein, the PCR reaction system was as follows: 4 μL cDNA, 1 μL forward primer (10 mM), 1 μL reverse primer (10 mM), 12.5 μL 2×Gloria HiFi (from Wuhan Abotek Biotechnology Co., Ltd., catalog number RK20717) and 6.5 μL pure water; PCR amplification program: 98°C pre-denaturation for 30 s, followed by 40 cycles of 98°C for 10 s, 64°C for 30 s, and 72°C for 30 s, and finally 72°C for 5 min, and the resulting reaction solution was stored at 4°C. The nucleotide sequences (5'-3') of the primer pairs for amplifying VL and VH are as follows, where F represents the forward primer and R represents the reverse primer:

[0086] VL-F: tgaattcgagctcggtacccatggacacgagggcccccac (SEQ ID NO. 18);

[0087] VL-R: cacacacgatggtgactgttccagttgccacctgatcag (SEQ ID NO. 19);

[0088] VH-F: tgaattcgagctcggtacccatggagactgggctgcgctg (SEQ ID NO. 20);

[0089] VH-R: gtagcctttgaccaggcagcccagggtcaccgtggagctg (SEQ ID NO. 21).

[0090] 5) Production and purification of rabbit monoclonal antibody genes: After purification of the light chain variable region and heavy chain variable region genes of the selected rabbit monoclonal antibodies, they were loaded onto expression vector pBR322 carrying the light chain constant region (CL) and heavy chain constant region (CH) encoding genes in advance. The mammalian expression vector pBR322 used is shown in Figure 3In the figure, pBR322 origin and f1 origin are replication promoters in Escherichia coli (E.Coli), Ampcillin is a plasmid resistance gene, CMV immearly promoter is a promoter in eukaryotes, SV40 PA terminator is a tailing signal, Light chain constant is the nucleic acid sequence of the light chain constant region (left figure), and Heavy chain constant is the nucleic acid sequence of the heavy chain constant region (right figure). The construction process is as follows: the mammalian cell expression vector pBR322 containing rabbit monoclonal antibodies CH and CL is subjected to conventional linearization treatment with NheI and XbaI restriction endonucleases respectively, the above-amplified PCR product (with a signal peptide encoding gene upstream) is purified, and the VL gene and VH gene are constructed into the corresponding mammalian expression vector by homologous recombination, and after verification by sequencing (sequencing work is completed by Jinkairui Biotechnology Co., Ltd.), the above-constructed expression vector containing the corresponding rabbit monoclonal antibody light chain gene and heavy chain gene is transfected into 293F cells together; after transfection, the cells are cultured for 72-96 hours to obtain a supernatant containing rabbit monoclonal antibodies against human CD44 protein. Rabbit monoclonal antibodies that recognize human CD44 protein are purified from the culture supernatant using proteinA affinity gel resin, and the affinity chromatography adopts conventional operations in the art, which will not be repeated here, and the purified antibody concentration is 1.5 mg / mL, and the purity is greater than 95%.

[0091] The signal peptide of this embodiment can adopt the antibody expression signal peptide sequence commonly used in the art, such as the patent "Rabbit monoclonal antibody against human interferon α2 and its application (publication number: CN116063487A, publication date: 2023-05-05)", the light chain variable region upstream has a signal peptide "MDTRAPTQLLGLLLLWLPGATF", and the encoding gene is "ATGGACACGAGGGCCCCCACTCAGCTGCTGGGACTGTTGCTCCTGTGGTTGCCTGGTGCAACTTTC"; the heavy chain variable region upstream has a signal peptide "METGLRWLLLVAVLKGVQC", and the encoding gene is "ATGGAGACTGGGCTGCGCTGGCTTCTCCTGGTGGCGGTGCTTAAGGGAGTACAGTGC".

[0092] The rabbit monoclonal antibody against human CD44 protein obtained in this example has a light chain constant region of a κ chain and a heavy chain constant region of an IgG1 type, and the amino acid (AA) sequences of the light chain and heavy chain and the nucleotide (DNA) sequences of the encoding genes are shown in Table 1. For convenience of description below, the light chain complementary determining regions CDR1, CDR2 and CDR3 are represented by LCDR1, LCDR2 and LCDR3, respectively, and the heavy chain complementary determining regions CDR1, CDR2 and CDR3 are represented by HCDR1, HCDR2 and HCDR3, respectively.

[0093] Table 1 Summary of sequence information of rabbit monoclonal antibodies of the present invention

[0094]

[0095]

[0096] Example 3 Western blot analysis (WB) of rabbit monoclonal antibodies

[0097] A human cervical cancer cell HeLa sample with high expression of CD44 protein was taken, and the recognition specificity of the rabbit monoclonal antibody of the present invention was detected by WB method, comprising the following steps: the aforementioned cell sample was lysed to obtain a protein extract, 7% polyacrylamide gel electrophoresis was performed, and the gel protein band was transferred to a PVDF membrane in an electrotransfer system according to a conventional method; the membrane was placed in a TBST blocking solution containing 3% skim milk powder and incubated at room temperature for 1 hour, and a rabbit monoclonal antibody against CD44 protein (primary antibody dilution ratio 1:10000, primary antibody working concentration 0.1μg / mL) was added, and incubated at 4°C overnight; then the membrane was washed with TBST, and a goat anti-rabbit secondary antibody working solution (purchased from Jackson ImmunoResearch, item number 111-035-045, secondary antibody dilution ratio 1:10000) was added, and incubated at room temperature for 1 hour; the membrane was washed with TBST again, and an ECL ultrasensitive color developing solution was added for development, and the results are shown in FIG. Figure 4 .

[0098] The full length of CD44 is 742aa, and the theoretical molecular weight is 82kd. Figure 4 It can be seen that the screened CD44 rabbit monoclonal antibody has good specificity, a single target band was detected in the HeLa cell lysate, and the actual detected molecular weight was consistent with the expected size, indicating that the rabbit monoclonal antibody can specifically recognize the human CD44 protein and has no nonspecific binding. The antibody has high specificity and good affinity for binding to the CD44 protein, which can effectively avoid false positive results and has high detection accuracy.

[0099] Example 4 Immunofluorescence analysis (IF) of rabbit monoclonal antibodies

[0100] Human cervical cancer cell HeLa and human epidermal cancer cell A-431 samples with high expression of CD44 protein were taken, and the recognition specificity of the monoclonal antibody of the present invention was detected by IF method, comprising the following steps: the HeLa cell sample was completely covered with 5% blank goat serum, placed in a 37°C constant temperature and humidity incubator for incubation for 30 minutes, the blocking solution was removed, and a rabbit monoclonal antibody working solution of anti-CD44 protein (primary antibody dilution ratio 1:200, primary antibody working concentration 0.5 μg / mL) prepared with TBS buffer was dripped on the sample, and placed at 4°C for incubation overnight, the sample was placed at room temperature, reheated for 15 minutes, the primary antibody working solution was removed, and the sample was washed with buffer TBST, and a goat anti-rabbit secondary antibody working solution (Alexa Fluor 500 4 ... 594AffiniPure Goat Anti-Rabbit IgG (H+L), purchased from Jackson, catalog number 111-585-003, secondary antibody dilution ratio 1:400), the sample needs to be completely covered, protected from light, incubated at 37°C for 1 hour, the secondary antibody working solution is removed, washed with TBST buffer, DAPI working solution is added to the sample, and incubated for 10 minutes; after removing the DAPI working solution and adding anti-fluorescence attenuation mounting medium, the sample is observed and the image is collected under a fluorescence microscope. The results are shown in Figure 5 The upper left and upper right pictures are confocal imaging of HeLa cells and A-431 cells using anti-CD44 protein rabbit monoclonal antibody (red), and the lower left picture is HeLa cells and A-431 cells using DAPI nuclear staining (blue) and merging red and blue to display the localization information of CD44 protein.

[0101] Through immunofluorescence detection, it can be seen that the rabbit monoclonal antibody of the present invention can specifically bind to the CD44 protein in the cell membrane and the intercellular matrix, which is consistent with its theoretical positioning, further proving that the rabbit monoclonal antibody prepared in the present application has good recognition specificity for the human CD44 protein.

[0102] Example 5 Immunohistochemistry (IHC) analysis of rabbit monoclonal antibodies

[0103] 1. Chip selection

[0104] Human CD44 protein is widely expressed in human tissue samples. The pathological tissue chip of this example (purchased from Bios, catalog number TMA000-24-H) includes human tonsil, human colon, human ovary, human liver, human extranodal NK / T cell lymphoma, human colon invasive adenocarcinoma, human endometrioid carcinoma, human hepatocellular carcinoma, human prostate adenocarcinoma, human high-grade urothelial carcinoma, human ovarian serous carcinoma, human hepatobiliary carcinoma, human malignant glioma, human breast, human cervix, human lung, human brain (neuron), human breast invasive ductal carcinoma, human cervical squamous cell carcinoma, human lung squamous cell carcinoma, human small cell lung cancer, human placenta, human endometrial stromal sarcoma, and human lung adenocarcinoma tissue samples. Except for human hepatocytes as a negative sample, the rest are positive samples.

[0105] 2. Immunohistochemistry (IHC) staining and analysis

[0106] Sample preparation and baking: Place the paraffin sections on the slice rack in the same direction and bake them in a 56°C constant temperature oven for 30 minutes; at the same time, place a cylinder of dewaxing solution in a 56°C constant temperature oven;

[0107] Dewaxing to water: Put the paraffin slices together with the slice rack into the dewaxing liquid 1 cylinder, then take them out from the thermostat and place them at room temperature. After 5 minutes, take out the slices and immerse them in the room temperature dewaxing liquid 2 cylinder, and put the paraffin slices into the cylinders in the order of dewaxing liquid 2, dewaxing liquid 3, anhydrous ethanol 1, anhydrous ethanol 2, and anhydrous ethanol 3. Each cylinder of the dewaxing liquid reagent cylinder is 5 minutes, and each cylinder of the anhydrous ethanol reagent cylinder is 3 minutes; wash the slices with running water for 3 minutes; the aforementioned dewaxing liquids 1-3 were purchased from Wuxi Jiangyuan Industrial Technology Trade Co., Ltd.;

[0108] Antigen retrieval: 0.01M Tris-EDTA retrieval solution (pH 9.0) high pressure heat retrieval;

[0109] Inactivation of endogenous peroxidase: Wash with PBS buffer three times, 1 min each time, remove the buffer on the slices; immerse the slices completely in 3% hydrogen peroxide solution and incubate at room temperature for 10 min;

[0110] Blocking: Wash with PBS buffer 3 times, 3 minutes each time, and remove the buffer on the slices; circle the tissue area to be tested on the slide with an immunohistochemical pen, and add PBS blocking solution in the circled area; place the slices horizontally in an incubation humid box with water at the bottom, incubate at room temperature for 30 minutes, and start timing from the addition of the blocking solution;

[0111] Primary antibody incubation: except for the blocking solution, add rabbit monoclonal antibody against human CD44 protein diluted with antibody diluent-PBS buffer (primary antibody dilution ratio 1:2500) on the tissue section, place it horizontally in the incubation wet box, and incubate it at room temperature for 60 minutes; remove the antibody working solution, rinse it quickly with PBS buffer once, and soak and wash it with buffer PBS three times, each time for 3 minutes; during the soaking and washing period, it needs to be repeatedly lifted up and down several times;

[0112] Secondary antibody incubation: add ready-to-use secondary antibody working solution (Dako REAL EnVision Detection System, Peroxidase / DAB, Rabbit / Mouse, HRP; Dako) to the tissue sections and place them horizontally in an incubation humidified box for incubation at room temperature for 25 min; remove the secondary antibody working solution on the sections, rinse quickly with PBS buffer once, and soak and wash with PBS buffer three times, each time for 3 min; during the soaking and washing period, lift up and down repeatedly;

[0113] Color development: Add color developing solution to the slices, and observe the color change closely under a microscope. After obtaining the appropriate staining intensity, immerse the slices in a large amount of distilled water to stop the color development. After the color development is stopped, wash the slices in running water for 10 minutes.

[0114] Counterstaining: Immerse the slightly drained tissue sections in Mayer's hematoxylin for counterstaining for 1 minute, then wash with running water for 3 minutes;

[0115] Bluing: Immerse the slightly drained slices in a saturated aqueous solution of lithium carbonate for 3 seconds, and then rinse with running water for 3 minutes;

[0116] Dehydration: Soak the washed slices in anhydrous ethanol once, lift them up and down several times during the soaking period, and take them out after 10 seconds; place them in a constant temperature air drying oven at 54-58℃ to completely dry;

[0117] Sealing: Add an appropriate amount of neutral gum to the center of the slice and cover it with a coverslip. The amount of glue added should be appropriate. After adding the coverslip, the tissue should be completely covered and no glue should overflow.

[0118] Finally, the slices were scanned. The results of immunohistochemical staining were divided into positive and negative. The positive signal was considered positive only when the cells or tissues that should theoretically show brown coloring and the background was low, that is, the cells or tissues that should theoretically show brown coloring were moderately stained, and the cells and tissues that should not be stained theoretically were not stained. The cell nucleus was counterstained with hematoxylin and appeared blue, which could show the background outline of the cells that were specifically immunostained, and was used to determine the subcellular localization of the target protein. The results showed that CD44 protein was expressed in the interstitial cells of human tonsil, human colon, human ovary, human extranodal NK / T cell lymphoma, human colon invasive adenocarcinoma, human endometrioid carcinoma, human hepatocellular carcinoma, human prostate adenocarcinoma, human high-grade urothelial carcinoma, human ovarian serous carcinoma, human hepatobiliary carcinoma, human malignant glioma, human breast, human cervix, human lung, human brain (neuron), human breast invasive ductal carcinoma, human cervical squamous cell carcinoma, human lung squamous cell carcinoma, human small cell lung cancer, human placenta, human endometrial stromal sarcoma and human lung adenocarcinoma samples. Some results are shown in Figure 6 , where the left picture shows the staining result of a human tonsil sample, and the right picture shows the staining result of a human liver sample. It should be noted that in human liver tissue, only Kupffer cells are positive, and other cells are negative. The immunohistochemical results of this sample are consistent with the theoretical staining and are determined to be negative samples.

[0119] The results of immunohistochemical staining showed that the rabbit monoclonal antibody against human CD44 protein was accurately localized in the cytoplasm and intercellular matrix, with clear staining and no nonspecific staining, and a clean background. According to the results of the section scan, among the positive samples, there was specific staining in 23 positive samples, with a sensitivity of 23 / 23=100%, and among the negative samples, 1 case was negative, with a specificity of 1 / 1=100%. It can be seen that the rabbit monoclonal antibody of the present invention can specifically recognize human CD44 protein, without nonspecific staining, and has the advantages of high accuracy and good reliability in detecting multiple pathological samples.

[0120] Example 6 Flow Cytometry (FCM) analysis of rabbit monoclonal antibodies

[0121] Take the cultured Hela cells and human breast cancer cell MCF-7 samples that highly express CD44 protein, centrifuge at 500g for 4min, and discard the supernatant. Wash once with 13mL PBS, discard the supernatant, add 3ml TrypLETM Express enzyme (1×) to digest the cells for 2min, observe the cell digestion status under a microscope, add culture medium to terminate digestion, blow and collect the cells into a centrifuge tube, centrifuge at 400g for 5min, and discard the supernatant. Resuspend the collected cells with 1mL PBS solution containing 0.5% BSA, centrifuge at 400g for 3min, repeat twice, and take 5×10 6 Resuspend the cells to 750 μL with 0.5% BSA in PBS and add 50 μL of cell suspension to each well of a 96-well plate.

[0122] Primary antibody incubation: 50 μL of rabbit monoclonal antibody working solution against human CD44 protein was added to each well (primary antibody working concentration was 10 μg / mL, 5 μg / mL, 2.5 μg / mL), shaken, and reacted at room temperature for 20 min; rabbit IgG (Kappa) (from Abclonal, product number AC042) was used as rabbit isotype control (Rabbit isotype control, used to eliminate background staining caused by nonspecific binding of antibodies to cells), and the working concentration of the isotype control antibody was 10 μg / mL.

[0123] Secondary antibody incubation: centrifuge at 400 g for 5 min, discard the supernatant, add 100 μL of fluorescent secondary antibody GαR 2°Ab (Alexa Fluor 647 conjugated goat anti-rabbit pAb, purchased from Jackson, catalog number 111-606-046) was resuspended and shaken in the dark and reacted at room temperature for 20 minutes.

[0124] Signal detection: Centrifuge at 400g for 5min, discard the supernatant, add 200μL PBS solution containing 0.5% BSA to resuspend, centrifuge at 400g for 5min, discard the supernatant, repeat twice. Resuspend the cells with 200μL PBS solution containing 0.5% BSA, and detect the fluorescence signal on a flow cytometer. Perform the analysis according to Beckman cytoflex flow analyzer use and maintenance SOP-105-AND-CA-008.

[0125] Flow cytometry test results are divided into: positive and negative. A positive result must have a specific signal transition on the cell to be considered positive, and a negative result must have no signal transition on the cell to be considered negative. Figure 7 As shown, the abscissa represents the relative intensity of the fluorescence signal / scattered light signal of the channel, the ordinate represents the corresponding number of cells, the red curve is the blank control test result without adding any antibody, the blue curve is the isotype control test result, and the orange curve is the CD44 antibody test result. After the rabbit monoclonal antibody of the present invention is combined with Hela cells and MCF-7 cells, the fluorescence transition signal is obvious, which can increase by an order of magnitude of 0.9-1.5, and increases with the increase of CD44 rabbit monoclonal antibody concentration, confirming that the rabbit monoclonal antibody against human CD44 protein has good specificity and high affinity for flow cytometry detection, and has no non-specific recognition.

[0126] The above description is only a preferred embodiment of the present invention and is not intended to limit the present invention. Any modifications, equivalent substitutions and improvements made within the spirit and principles of the present invention should be included in the protection scope of the present invention.

Claims

1. A rabbit monoclonal antibody against human CD44 protein, characterized in that: It comprises a light chain variable region and a heavy chain variable region, each of which comprises three complementarity determining regions, wherein: The amino acid sequences of light chain CDR1, light chain CDR2 and light chain CDR3 are shown in SEQ ID NO.5, SEQ ID NO.6 and SEQ ID NO.7, respectively; The amino acid sequences of the heavy chain CDR1, heavy chain CDR2 and heavy chain CDR3 are shown in SEQ ID NO.8, SEQ ID NO.9 and SEQ ID NO.10, respectively.

2. The rabbit monoclonal antibody against human CD44 protein according to claim 1, characterized in that: The amino acid sequence of the light chain variable region is shown in SEQ ID NO.3, and the amino acid sequence of the heavy chain variable region is shown in SEQ ID NO.

4.

3. The rabbit monoclonal antibody against human CD44 protein according to claim 1, characterized in that: Also includes a light chain constant region and a heavy chain constant region, wherein the light chain constant region and the light chain variable region constitute a light chain, and the heavy chain constant region and the heavy chain variable region constitute a heavy chain; The amino acid sequence of the light chain is shown in SEQ ID NO.1, and the amino acid sequence of the heavy chain is shown in SEQ ID NO.

2.

4. The rabbit monoclonal antibody against human CD44 protein according to claim 1 or 2, characterized in that: The rabbit monoclonal antibody is a full-length antibody or an antibody fragment with immunological activity; The antibody fragment is selected from at least one of a Fab fragment, a F(ab)2 fragment, a Fv fragment, a (Fv)2 fragment, a scFv fragment and a sc(Fv)2 fragment.

5. A nucleic acid molecule, characterized in that The nucleic acid molecule encodes the rabbit monoclonal antibody against human CD44 protein according to any one of claims 1 to 4.

6. The nucleic acid molecule according to claim 5, characterized in that The nucleotide sequence of the light chain variable region of the rabbit monoclonal antibody is shown in SEQ ID NO.12, and the nucleotide sequence of the heavy chain variable region is shown in SEQ ID NO.

14.

7. The nucleic acid molecule according to claim 5, characterized in that The nucleotide sequence of the light chain of the rabbit monoclonal antibody is shown in SEQ ID NO.11, and the nucleotide sequence of the heavy chain is shown in SEQ ID NO.

13.

8. A recombinant vector, characterized in that: Comprising the nucleic acid molecule according to any one of claims 5 to 7.

9. Use of the rabbit monoclonal antibody against human CD44 protein according to any one of claims 1 to 4 in the preparation of a reagent and / or a kit for immunodetection of human CD44 protein.

10. Use of the rabbit monoclonal antibody against human CD44 protein according to claim 9 in the preparation of a reagent and / or a kit for immunodetection of human CD44 protein, characterized in that: The immunoassay method is selected from immunoblotting, enzyme immunoassay, immunofluorescence, immunohistochemistry or flow cytometry; The immunoassay samples include serum, cells or tissues, wherein the cells include one or more of human cervical cancer cells, human epidermal cancer cells and human breast cancer cells, and the tissues include one or more of human tonsils, human colon, human ovaries, human extranodal NK / T cell lymphoma, human colon invasive adenocarcinoma, human endometrioid carcinoma, human hepatocellular carcinoma, human prostate adenocarcinoma, human high-grade urothelial carcinoma, human ovarian serous carcinoma, human hepatobiliary carcinoma, human malignant glioma, human breast, human cervix, human lung, human brain, human breast invasive ductal carcinoma, human cervical squamous cell carcinoma, human lung squamous cell carcinoma, human small cell lung cancer, human placenta, human endometrial stromal sarcoma and human lung adenocarcinoma.

11. Use of the rabbit monoclonal antibody against human CD44 protein according to claim 10 in the preparation of a reagent and / or a kit for immunodetection of human CD44 protein, characterized in that: The enzyme immunoassay method is enzyme-linked immunosorbent assay or enzyme-linked immunospot assay.

Citation Information

Patent Citations

  • Method for efficiently separating single antigen-specific B lymphocyte from spleen cells

    CN110016462A

  • B lymphocyte in vitro culture system and applications thereof

    CN111518765A

  • Anti-human interferon alpha 2 rabbit monoclonal antibody and application thereof

    CN116063487A

  • Anti-human CD10 protein rabbit monoclonal antibody and application thereof

    CN116731181A

  • Anti-human CD13 protein rabbit monoclonal antibody and application thereof

    CN116731183A